KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Acadia Pharmaceuticals (ACAD) Accumulated Expenses (2016 - 2025)

Acadia Pharmaceuticals (ACAD) has 16 years of Accumulated Expenses data on record, last reported at $266.2 million in Q4 2025.

  • For Q4 2025, Accumulated Expenses rose 2193.34% year-over-year to $266.2 million; the TTM value through Dec 2025 reached $266.2 million, up 2193.34%, while the annual FY2025 figure was $266.2 million, 2193.34% up from the prior year.
  • Accumulated Expenses reached $266.2 million in Q4 2025 per ACAD's latest filing, up from $11.6 million in the prior quarter.
  • Across five years, Accumulated Expenses topped out at $266.2 million in Q4 2025 and bottomed at $11.6 million in Q4 2024.
  • Average Accumulated Expenses over 5 years is $108.1 million, with a median of $94.9 million recorded in 2021.
  • Peak YoY movement for Accumulated Expenses: tumbled 95.1% in 2024, then soared 2193.34% in 2025.
  • A 5-year view of Accumulated Expenses shows it stood at $89.2 million in 2021, then crashed by 68.58% to $28.0 million in 2022, then surged by 744.7% to $236.7 million in 2023, then crashed by 95.1% to $11.6 million in 2024, then skyrocketed by 2193.34% to $266.2 million in 2025.
  • Per Business Quant database, its latest 3 readings for Accumulated Expenses were $266.2 million in Q4 2025, $11.6 million in Q4 2024, and $236.7 million in Q4 2023.